ADIOS™ TABLETS
2. Qualitative and quantitative composition
Butternut bark (Juglans Cinerama L.) 20 mg; Dandelion root (Tamarack officialese Weber ex Wigs.) 30 mg; Dry extract Blood leaf (Peumus boldus Molina) (4:1) 34 mg, Extraction solvent: water; Dry extract Bladder wrack phallus (Mucus vesiculate L.) (5:1) 45 mg, Extraction solvent: 30% methanol.
For full list of excipients, see section List of excipients.
Sucrose 186 mg; Iodine 54 micrograms (see section 'Special warnings and precautions for use').
3. Pharmaceutical form
Peachy orange, biconvex sugar-coated tablets.
4. Clinical particulars
4.1 Therapeutic indications
A traditional herbal medicinal product used as an aid to slimming as part of a calorie controlled diet, based on traditional use only.
4.2 Phonology and method of administration
For oral use only. Adults (18 years and above): One tablet three or four times a day at mealtimes.
This product should be taken as part of a calorie-controlled diet and extra exercise.
If symptoms do not improve or worsen during the use of this medicinal product, a doctor or a qualified healthcare practitioner should be consulted.
The use in children and adolescents under 18 years and the elderly is not recommended (see section 'Special warnings and precautions for use').
4.3 Contraindications
Hypersensitivity to the active substances or to iodine or to plants of the Easterner (Composite) family or any of the excipients.
Patients with a thyroid disorder.
Obstruction of bile duct, cholecystitis, liver disease, gallstones, active peptic ulcer and any other billiard disorders that require medical supervision and advice.
4.4 Special warnings and precautions for use
Do not exceed the stated dose.
The use in children and adolescents under 18 years and the elderly is not recommended because data are insufficient and medical advice should be sought.
The use in patients with renal failure and/or diabetes, and/or heart failure because of possible complications due to hyperglycemia.
Do not take with other medicines or dietary supplements containing iodine.
Contains sucrose; patients with rare hereditary problems of lactose or fructose intolerance, glucose-lactose absorption, the Lapp lactate deficiency or sucrose-isometrically insufficiency should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
No studies have been carried out to determine if drug interactions occur with this product.
This product can theoretically have an effect on anticoagulant treatments. Patients taking anticoagulant treatments should not use this product.
Do not take with other medicines or dietary supplements containing iodine.
Do not take with medicines for thyroid disorders.
4.6 Pregnancy and lactation
Safety during pregnancy and lactation has not been established.
In the absence of sufficient data the use in pregnancy and lactation is not recommended.
Studies on the effects on fertility have not been performed.
4.7 Effects on ability to drive and use machines
No studies on the effects of this product on the ability to drive or operate machinery have been performed.
4.8 Undesirable effects
May cause diarrhea. The frequency is unknown.
Gastric pain and hyper acidity may occur with Dandelion root. The frequency is not known.
Hypersensitivity (prophylaxis) has been reported with Blood leaf. The frequency is not known.
If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellow card.
4.9 Overdose
An overdose may lead to thyroid disorders such as hyperthyroidism, toxicologists, sub clinical hypothyroidism, Hashish's hypothyroidism.
5. Pharmacological properties
5.1 Pharmacologic properties
Not required as per Article 16 c(1)(a)(iii) of Directive 2001/83/EC as amended.
5.2 Pharmacokinetic properties
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
5.3 Preclinical safety data
Tests on reproductive toxicity, carcinogenicity and carcinogenicity have not been performed.
Tests on reproductive toxicity have been performed with a dry ethanolic extract of boldo leaf and boldine administered orally to pregnant rats. Results showed anatomical alterations in the foetus and a few cases of abortion at high doses.
6. Pharmaceutical particulars
6.1 List of excipients
Sucrose; Cellulose; Sodium Starch Collate; Talc; Silicon Dioxide; Re-gelatinous Starch; Magnesium Separate; Kaolin; Shellac; Titanium Dioxide (E171); Red Iron Oxide (E172); Yellow Iron Oxide (E172).
6.2 Incompatibilities
None.
6.3 Shelf life
36 months.
6.4 Special precautions for storage
Do not store above 25°C. Store in the original package.
6.5 Nature and contents of container
White plastic container with tamper-evident molded cap or integral plastic cap, containing 100 tablets.
6.6 Special precautions for disposal and other handling
No special requirements.
---------------------------------------------------------------------------------------------------------------
Labels :
adios tablets Nasdaq . adios tablets reviews . adios tablets boots . adios tablets Tesco . adios tablets savers. adios tablets do they work . adios tablets side effects . adios tablets Spanish . adios tablets Spain . adios tablets amazon . adios max tablets Nasdaq .
0 تعليقات